A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by the gene ROS1 (ROS1), or neurotrophic receptor kinase genes encoding TRK kinase family (NTRK1-3) alterations to estimate the Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) and select the Pediatric Recommended Phase 2 Dose (RP2D). Phase 2 will determine the anti-tumor activity of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring ROS1 or NTRK1-3 alterations.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzona genetyczna zmiana ROS1 (mutacja, fuzja lub wzmożenie) lub fuzja NTRK1-3 w badaniu laboratoryjnym
- •Faza 1: poniżej 12 lat; Faza 2: od 12 do 25 lat
- •Wcześniejsza chemioterapia jest dozwolona
- •Wcześniejsza immunoterapia jest dozwolona
- •Ustąpienie skutków ubocznych poprzednich terapii antynowotworowych (oprócz łysienia)
- •Wymierny nowotwór w momencie wpisania do badania
- •Pacjenci z guzami mózgu muszą być neurologicznie stabilni
- •Oczekiwana długość życia co najmniej 12 tygodni
✗ Disqualifies
- •Neuroblastoma z tylko szpikową chorobą mierzalną wyłącznie aspiracją szpiku
Simplified criteria — AI translation
Trial details
- Maximum age
- 25 Years
- Last updated (source)
- September 25, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (68)
Children's Hospital Los Angeles
Los Angeles, United States
University of California at Los Angeles
Los Angeles, United States
Children's Hospital Colorado - Anschutz Medical Campus
Aurora, United States
Local Institution - 2105
Orlando, United States
Local Institution - 2120
Orlando, United States
Children's Healthcare of Atlanta - Egleston Hospital
Atlanta, United States
Maine Medical Center
Scarborough, United States
Dana Farber Cancer Institute.
Boston, United States
Washington University School of Medicine in St. Louis
St Louis, United States
Local Institution - 2110
New Brunswick, United States
Local Institution - 2102
New York, United States
Levine Children's Hospital- Pediatric Neuro-Oncology
Charlotte, United States
Local Institution - 2112
Cleveland, United States
Local Institution - 2114
Hershey, United States
Children's Hospital of Philadelphia-Center for Childhood Cancer Research
Philadelphia, United States
St. Jude Children's Research Hospital
Memphis, United States
The University of Texas Southwestern Medical Center - Harold C Simmons Comprehensive Cancer Center
Dallas, United States
Baylor College of Medicine
Houston, United States
Local Institution - 2104
Houston, United States
Children's Hospital of Richmond at VCU
Richmond, United States
Local Institution - 6104
Randwick, Australia
Local Institution - 6103
Westmead, Australia
Children's Health Queensland Hospital and Health Service
South Brisbane, Australia
Perth Childrens Hospital
Nedlands, Australia
University Of Calgary
Calgary, Canada
Stollery Children'S Hospital
Edmonton, Canada
Children'S Hospital Of Eastern Ontario
Ottawa, Canada
St Justine Hospital
Montreal, Canada
Rigshospitalet - Glostrup
Copenhagen, Denmark
Local Institution - 6111
Lyon, France
Centre Hospitalier Universitaire D'Angers
Angers, France
Centre Hospitalier Universitaire de Bordeaux - Groupe Hospitalier Pellegrin
Bordeaux, France
Institut d Hematologie et d Oncologie Pediatriques
Lyon, France
Hôpitaux Universitaires de Marseille Timone
Marseille, France
Local Institution - 6110
Marseille, France
Local Institution - 6112
Nantes, France
Local Institution - 6109
Paris, France
Institut Gustave-Roussy
Villejuif, France
Local Institution - 6108
Villejuif, France
Fondazione IRCCS - Istituto Nazionale dei Tumori
Milan, Italy
Local Institution - 6113
Padova, Italy
Local Institution - 4302
Rome, Italy
Local Institution - 6114
Torino, Italy
National University Hospital
Singapore, Singapore
KK Women's and Children's Hospital
Singapore, Singapore
Local Institution - 6303
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Local Institution - 6304
Seoul, South Korea
Hospital Sant Joan De Deu
Esplugues de Llobregat, Spain
Clínica Universidad de navarra
Pamplona, Spain
Local Institution - 6105
Barcelona, Spain
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Infantil Universitario Nino Jesus
Madrid, Spain
Local Institution - 6106
Madrid, Spain
Clinica Universidad de Navarra
Madrid, Spain
HM Sanchinarro University Hospital
Madrid, Spain
Hospital Universitario Virgen del Rocio
Seville, Spain
Hospital Universitario Y Politecnico La Fe
Valencia, Spain
Local Institution - 6107
Valencia, Spain
Local Institution - 6202
Taipei, Taiwan
Taipei Medical University Hospital
Taipei, Taiwan
Alder Hey Children's NHS Foundation Trust
Liverpool, United Kingdom
Local Institution - 4403
Birmingham, United Kingdom
University Hospital of Wales
Cardiff, United Kingdom
Royal Hosp. for Children
Glasgow, United Kingdom
The Royal Marsden NHS Foundation Trust
London, United Kingdom
Great Ormond Street Hospital For Children NHS Foundation Trust
London, United Kingdom
Trial contact
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
First line of the email MUST contain NCT # and Site #.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/5/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.